NCT00483301View on ClinicalTrials.gov

A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL

Enrollment

34

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions

Malignant Melanoma

Interventions

DRUG

Sorafenib (BAY 43-9006)

dosage

DRUG

ABI-007(Abraxane)

dosage

Trial Locations (2)

33140

Mt. Sinai Medical Center, Miami Beach

90025

Dr. Steven O'Day, Los Angeles

Sponsors

Collaborators (2)

Celgene Corporation

All Listed Sponsors

collaborator

Celgene Corporation

INDUSTRY

collaborator

Bayer

INDUSTRY

lead

Mt. Sinai Medical Center, Miami

OTHER